VolitionRX Ltd is a US-based multi-national life sciences company. It is engaged in developing easy to use blood-based tests to accurately diagnose a range of cancers. The development pipeline includes assays to be used for symptomatic patients or asymptomatic populations. The company has developed more than 30 blood-based assays to detect specific biomarkers. It also develops Nucleosomics tests for several major cancers including CRC, pancreatic, lung and aggressive prostate. In addition, the company engages in the process of developing HyperGenomics tissue and blood-based tests to determine disease subtype following initial diagnosis and to help decide the appropriate therapy.
| Website: | www.volitionrx.com |
| Email: | investorrelations@volitionrx.com |
| Address: | 1 Scotts Road |
| Address 2: | No. 24-05 Shaw Centre |
| City / Town: | Singapore |
| Country: | SGP |
| Postal Code: | 228208 |
| Exchange: | AMX |
| CEO: | Cameron John. Reynolds |
| Employees: | 44 |
| NAICS: | In-Vitro Diagnostic Substance Manufacturing(325413) |
Preliminary data shows identification of 94% of aggressive prostate cancers (Image: VolitionRx).
VolitionRx Ltd is dedicated to revolutionizing cancer diagnosis by developing noninvasive diagnostic tests based on its Nucleosomics® technology.
Micro-cap stocks suffer from all sorts of ills. They are often illiquid, and companies can be unable to raise new funds under reasonable terms, if at all. Investing in these equities requires
Brooksie’s Daily Stock Market Blog: An edge before the market opens.Monday, April 4, 2011 9:24 am EDTDJIA: 12,376.72 S&P 500: 1332.41 Nasdaq Composite: 2789.60 Russell 2000:
VolitionRX Ltd is a US-based multi-national life sciences company. It is engaged in developing easy to use blood-based tests to accurately diagnose a range of cancers. The development pipeline includes assays to be used for symptomatic patients or asymptomatic populations. The company has developed more than 30 blood-based assays to detect specific biomarkers. It also develops Nucleosomics tests for several major cancers including CRC, pancreatic, lung and aggressive prostate. In addition, the company engages in the process of developing HyperGenomics tissue and blood-based tests to determine disease subtype following initial diagnosis and to help decide the appropriate therapy.
| Website: | www.volitionrx.com |
| Email: | investorrelations@volitionrx.com |
| Address: | 1 Scotts Road |
| Address 2: | No. 24-05 Shaw Centre |
| City / Town: | Singapore |
| Country: | SGP |
| Postal Code: | 228208 |
| Exchange: | AMX |
| CEO: | Cameron John. Reynolds |
| Employees: | 44 |
| NAICS: | In-Vitro Diagnostic Substance Manufacturing(325413) |
Preliminary data shows identification of 94% of aggressive prostate cancers (Image: VolitionRx).
VolitionRx Ltd is dedicated to revolutionizing cancer diagnosis by developing noninvasive diagnostic tests based on its Nucleosomics® technology.
Micro-cap stocks suffer from all sorts of ills. They are often illiquid, and companies can be unable to raise new funds under reasonable terms, if at all. Investing in these equities requires
Brooksie’s Daily Stock Market Blog: An edge before the market opens.Monday, April 4, 2011 9:24 am EDTDJIA: 12,376.72 S&P 500: 1332.41 Nasdaq Composite: 2789.60 Russell 2000:
| Last Price 4.48 | Change $ -0.1 | Change % -2.18 | Tick N/A |
| Bid N/A | Bid Size 0.00 | Ask N/A | Ask Size 0.00 |
| Open 4.60 | High 4.66 | Low 4.42 | Prev Close 4.58 |
| Last Trade | Volume 73,953 | 52 Wk Hi 6.84 | 52 Wk Low 1.67 |
| Market Cap 184.1 mi | Ex-Div Date N/A | Div Rate N/A | Yield N/A |
| Shares 41,092,340.00 | EPS (TTM) -0.44 | PE Ratio N/A | Exchange NYSE American |
|
|
|
|
| Last 3 Mo | Last 12 Mo | |
|---|---|---|
| Number of Insider Trades | 0 | 3 |
| Number of Buys | 0 | 3 |
| Number of Sells | 0 | 0 |
| Net Activity | 0 | 10010 |
| Last 10 Buys | Shares |
|---|---|
| David Vanston | 1,000 |
| Rodney Gerard Rootsaert | 1,000 |
| Cameron John. Reynolds | 1,000 |
| David M. Kratochvil | 1,000 |
| Cameron John. Reynolds | 1,000 |
| Cameron John. Reynolds | 1,000 |
| Guy Innes | 1,000 |
| Guy Innes | 1,000 |
| Guy Innes | 1,000 |
| Guy Innes | 1,000 |
| Last 10 Sell | Shares |
|---|---|
| Cameron John. Reynolds | 1,000 |
| Current | 1 Week Ago | 2 Weeks Ago | 3 Weeks Ago | |
|---|---|---|---|---|
| High Target Price Estimate | 8 | 8 | 8 | 8 |
| Low Target Price Estimate | 5 | 5 | 5 | 5 |
| Mean Target Price Estimate | 6.6 | 6.6 | 6.67 | 6.6 |
| Standard Deviation | 1.14 | 1.14 | 1.53 | 1.14 |
| Date of Most Recent Estimate | 06/04/18 | 05/23/18 | 05/18/18 | 06/04/18 |
| Form Type | Form Description | Pages | Date |
|---|---|---|---|
| 10-Q | Quarterly report with a continuing view of a company's financial position | 28 | 2018-05-10 |
| 8-K | Report of unscheduled material events or corporate changes. | 7 | 2018-05-10 |
| 8-K | Report of unscheduled material events or corporate changes. | 36 | 2018-03-12 |
| 424B5 | Prospectus filed under Rule 424(b)(5) | 40 | 2018-03-09 |
| 424B5 | Prospectus filed under Rule 424(b)(5) | 40 | 2018-03-08 |
| 10-K | Annual report with a comprehensive overview of the company | 82 | 2018-03-01 |
| 8-K | Report of unscheduled material events or corporate changes. | 7 | 2018-03-01 |
| SC 13G/A | Amendment to the SC 13G filing | 6 | 2018-02-14 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-01-25 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-01-25 |
| Current | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
|---|---|---|---|---|
| Strong Buy | 3 | 1 | 2 | 2 |
| Moderate Buy | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 |
| Moderate Sell | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 |
| Mean Rec. | 1 | 1 | 1 | 1 |
© 2019 Equities
* All dates and time are being displayed in Eastern Standard Time (EST).
Gathering Data... Please wait